Pulmonx, Corp (LUNG) files for IPO.

The IPO of Pulmonx, Corp. will take place on September 30, 2020. Pulmonx is a a medical technology company that provides a minimally invasive treatment for patients with severe emphysema - a chronic obstructive pulmonary disease. The company’s offering includes: The Zephyr endobronchial valve, The Chartis pulmonary assessment system and StratX lung analysis platform. Such an offering is intended for the treatment of patients with severe emphysema, who, despite treatment, still have serious symptoms of the disease, and are either unwilling or unsuitable for surgical intervention.
The company’s expected value after the IPO will be $642 million.
Listed underwriters of the IPO are BofA Securities, Morgan Stanley, Stifel, Wells Fargo Securities, and Canaccord Genuity.